Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study - Yong, K; Hinsley, S; Sherratt, D; Kendall, J; Brown, SR; Flanagan, L; Williams, C; Cavenagh, J; Kaiser, M; Rabin, NK; Ramasamy, K; Garg, M; et al. (AMER SOC HEMATOLOGY, 2018)